Czechia· CZ-0223080
NERLYNX
A neratinib product containing neratinib maleate, registered in Czechia by PIERRE FABRE MEDICAMENT, Lavaur. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Neratinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EH02 (neratinib), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Neratinib · ATC L01EH02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- NERATINIB MALEATE
- Manufacturer
- PIERRE FABRE MEDICAMENT, Lavaur
- Country
- Czechia (CZ)
- ATC code
- L01EH02
- ATC class
- Neratinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl0223080180CZK 96633.8
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for neratinib.
Graded by severity as the source publishes them — 97 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Neratinib · interactions on record
226 records
- 97 severe
- 123 moderate
- 6 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Neratinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNerlynx 40 mgPierre Fabre Médicament
- SwitzerlandNerlynx 40 mg, FilmtablettenPierre Fabre Pharma SA
- SpainNERLYNX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPierre Fabre Medicament
- FinlandNerlynxPierre Fabre Medicament
- IrelandNerlynx 40 mg Film-coated tabletPierre Fabre Medicament
- IcelandNerlynxPierre Fabre Medicament
- NetherlandsNerlynx 40 mg, filmomhulde tablettenPierre Fabre Medicament
- NorwayNerlynxPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Nerlynx
- Liechtenstein · Nerlynx
- Norway · Nerlynx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ed8e588d-692a-4eb8-bc7e-04fa4324b911 GET /v1/drugs/ed8e588d-692a-4eb8-bc7e-04fa4324b911?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "TBL FLM",
"source": "sukl",
"strength": "40MG",
"pack_size": "180",
"substance": "NERATINIB MALEATE",
"cz_kod_sukl": "0223080",
"product_type": "CH",
"substance_codes": "21452",
"registration_state": "R",
"registration_number": "EU/1/18/1311/001"
}See everything about neratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.